English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18074/20272 (89%)
造訪人次 : 4072730      線上人數 : 925
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/28694


    標題: Serum vascular adhesion protein-1 predicts all-cause mortality and cancer-related mortality in subjects with colorectal cancer
    作者: Li, Yu-I
    Hung, Ji-Shiang
    Yu, Tse-Ya
    Liou, Jyh-Ming
    Wei, Jung-Nan
    Kao, Hsien-Li
    Chuang, Lee-Ming
    Shun, Chia-Tung
    Lee, Po-Huang
    Lai, Hong-Shiee
    Su, Chien-Yin
    Li, Hung-Yuan
    Liang, Jin-Tung
    貢獻者: 職業安全衛生系
    關鍵字: Vascular adhesion protein-1
    Semicarbazide-sensitive amine oxidase
    Primary amine oxidase
    Mortality
    Colorectal cancer
    日期: 2014-01
    上傳時間: 2015-05-06 21:25:25 (UTC+8)
    出版者: Elsevier Science Bv
    摘要: Background: Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 can predict cancer mortality, including colorectal cancer (CRC) mortality, in type 2 diabetic subjects. However, it remains unknown if serum VAP-1 can predict mortality in CRC patients. This prospective cohort study investigates if serum VAP-1 is a novel biomarker for mortality prediction in CRC. Methods: We enrolled 300 CRC patients. Preoperative serum VAP-1 was measured by time-resolved immunofluorometric assay. They were followed until September 2009 or death, which was ascertained by the National Death Registration System. Results: The median follow-up period was 4.7 years. Compared with normal counterpart, VAP-1 immunoactivity was upregulated in CRC tissues, especially at the invasion front. Serum VAP-1 can independently predict all-cause mortality (HR: 1.0026, 95% Cl: 1.0003-1.0050, P < 0.05) and cancer-related mortality (HR: 1.0026, 95% Cl: 1.0001-1.0050, P <0.05). A risk score composed of age, gender, carcinoembryonic antigen (CEA) >5 ng/ml, tumor grading, tumor staging, and serum VAP-1 could stratify CRC patients into low-, intermediate-, and high-risk subgroups, with a 5-year mortality rate of 10%, 34%, and 78%, respectively. Conclusions: Serum VAP-1 predicts mortality independently and improves risk stratification in CRC subjects. (C) 2013 Elsevier B.V. All rights reserved.
    關聯: Clinica Chimica Acta, v.428 n., pp.51-56
    顯示於類別:[職業安全衛生系(含防災所)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML1867檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋